Spirulina and Raynaud’s syndrome.

Raynaud’s pathophysiology

Raynaud’s phenomenon affects 3–5% of the population (primary Raynaud’s) with a higher prevalence in women and in people with connective tissue diseases (secondary Raynaud’s in scleroderma, lupus, RA).

The characteristic colour change (white → blue → red on rewarming) reflects the sequence of vasospasm, ischaemia, and reactive hyperaemia. The core pathological mechanisms:

• Endothelial nitric oxide insufficiency:Digital arteries in Raynaud’s patients show reduced eNOS (endothelial nitric oxide synthase) activity and increased ROS destruction of NO — resulting in reduced vasodilatory capacity
• Exaggerated sympathetic response:Alpha-2 adrenergic receptors on digital vessels are more sensitive to cold-induced activation in Raynaud’s patients
• Endothelin-1 excess:Elevated ET-1 (potent vasoconstrictor) is found in both primary and secondary Raynaud’s
• Platelet activation: Platelet aggregation and thromboxane A2 release contribute to digital ischaemia during severe attacks

Spirulina’s nitric oxide mechanisms

eNOS upregulation and NO protection

Phycocyanin has two relevant effects on the nitric oxide pathway:

• Phycocyanobilin inhibits NADPH oxidase — reducing endothelial superoxide production. Superoxide rapidly destroys NO (forming peroxynitrite) — the primary mechanism of NO insufficiency in vascular disease. Reducing superoxide increases NO availability from the same eNOS activity.
• In vitro studies show phycocyanin upregulates eNOS expression in endothelial cells — increasing NO production directly

These are the same mechanisms responsible for spirulina’s documented blood pressure reduction (Ku et al., 2013) and the exercise performance trials showing improved VO₂max. The digital vasodilation benefit in Raynaud’s would operate through the same pathway.

L-arginine as NO substrate

L-arginine is the amino acid substrate for eNOS — without adequate arginine, NO synthesis is substrate-limited. Spirulina contains approximately 4–5% L-arginine by dry weight — 200–250 mg per 5 g serving.

While arginine supplementation at high doses (6–9 g/day) has shown benefit in vascular conditions, food-level arginine from spirulina contributes to substrate availability without reaching pharmacological doses.

GLA and prostaglandin balance

Spirulina’s GLA generates PGE1 — a vasodilatory prostaglandin that directly counteracts the vasoconstrictor thromboxane A2 involved in Raynaud’s attacks. Evening primrose oil (high GLA) has been studied for Raynaud’s with mixed but generally positive results for attack frequency — spirulina provides food-level GLA through the same mechanism.

Secondary Raynaud’s: the autoimmune caveat

Secondary Raynaud’s occurs in the context of connective tissue diseases — particularly scleroderma (systemic sclerosis), lupus, and RA. In these cases:

• The primary condition (especially SLE or scleroderma) takes precedence in the risk-benefit assessment
• Spirulina’s immune-stimulating properties are a concern in active autoimmune disease — see the lupus and autoimmune guides
• For secondary Raynaud’s in scleroderma: discuss with a rheumatologist before starting

For primary Raynaud’s (no underlying autoimmune disease), the autoimmune concern does not apply and spirulina is a reasonable nutritional approach.

What the evidence shows

No dedicated spirulina trial in Raynaud’s patients exists. The evidence base for the NO mechanism:

• Blood pressure RCT (Ku et al., 2013): 4.5 g/day spirulina reduced systolic BP by ~8 mmHg — consistent with meaningful endothelial NO enhancement
• Exercise trials: spirulina improves VO₂max and endurance consistent with improved tissue oxygen delivery — an indirect indicator of vascular NO function
• In vitro: phycocyanin upregulates eNOS and protects NO from superoxide destruction — direct mechanistic evidence

Practical protocol for Raynaud’s

1. Dose: 5 g/day with vitamin C (for iron absorption; vitamin C also independently supports eNOS activity as a cofactor for BH4 regeneration). Targeting 300–500 mg/day phycocyanin from quality spirulina.
2. Duration: The endothelial NO effect requires weeks to develop — assess at 8–12 weeks. Tracking attack frequency (number per week) and severity before and after gives objective data.
3. Complementary approaches:Magnesium glycinate (300 mg/day) is also a vasodilator relevant to Raynaud’s; fish oil/algal omega-3 shifts thromboxane balance. All share the GLA/prostaglandin mechanism with spirulina.
4. Avoid caffeine at dose time:Caffeine is a vasoconstrictor and is one of the common Raynaud’s triggers. Pairing spirulina with coffee reduces both iron absorption and any potential vasodilatory benefit.
5. Medical treatment first:Calcium channel blockers (nifedipine) and PDE5 inhibitors (sildenafil) are the established pharmacological treatments for frequent or severe Raynaud’s. Spirulina is an adjunct — not a replacement.